The latest research result from a Canadian research team: This weight loss drug increases the risk of pancreatitis by 900%!

The internationally renowned medical journal "Journal of the American Medical Association" published an article on weight loss drugs on the 5th, introducing the latest research results of a researcher. The research results have poured cold water on the currently popular GLP-1 type of weight loss drugs

The internationally renowned medical journal "Journal of the American Medical Association" published an article on weight loss drugs on the 5th, introducing the latest research results of a researcher. The research results have poured cold water on the currently popular GLP-1 type of weight loss drugs. Research has pointed out that drugs such as Smegglutide developed by Novo Nordisk in Denmark may increase the risk of users suffering from severe gastrointestinal diseases.

The new research findings were made by a research team at the University of British Columbia in Canada. Researchers say that although two GLP-1 drugs developed by Novo Nordisk have been approved for weight loss in some countries, due to the relatively small number of participants in clinical trials and short follow-up time, very rare adverse reactions cannot be detected. This study analyzed a diagnostic and prescription database containing 16 million patient information, and ultimately selected over 5400 valid records.

Compared with the incidence of serious side effects of another type of weight loss medication - bupropion/naltrexone, the risk of gastric paralysis associated with GLP-1 weight loss medication increased by nearly four times, the risk of pancreatitis increased by nine times, and the risk of intestinal obstruction increased by four times. The researchers said that the side effects will not change depending on the user's purpose, whether it is used to treat diabetes or lose weight. Currently, Novo Nordisk has not commented on this latest study. Since the beginning of this year, driven by the hot sales of its drug company Meglutide, Novo Nordisk's stock price has skyrocketed. In September of this year, the company's market value surpassed that of LVMH and became the highest in Europe.

Source: CCTV Finance

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])